三阴性乳腺癌
癌症研究
核糖体蛋白s6
生物
安普克
mTORC1型
转移
PI3K/AKT/mTOR通路
乳腺癌
P70-S6激酶1
细胞周期蛋白D1
信号转导
激酶
细胞周期
细胞生物学
癌症
蛋白激酶A
遗传学
作者
Fumi Tetsuo,Masaki Arioka,Koichi Miura,Takeru Inoue,Kazunobu Igawa,Katsuhiko Tomooka,Fumi Takahashi‐Yanaga,Toshiyuki Sasaguri
出处
期刊:Oncogene
[Springer Nature]
日期:2021-07-24
卷期号:40 (37): 5579-5589
被引量:20
标识
DOI:10.1038/s41388-021-01958-4
摘要
We have previously reported that the differentiation-inducing factor-1 (DIF-1), a compound identified in Dictyostelium discoideum, suppresses the growth of MCF-7 breast cancer cells by inactivating p70 ribosomal protein S6 kinase (p70S6K). Therefore, we first examined whether the same mechanism operates in other breast cancer cells, especially triple-negative breast cancer (TNBC), the most aggressive and refractory phenotype of breast cancer. We also investigated the mechanism by which DIF-1 suppresses p70S6K by focusing on the AMPK-mTORC1 system. We found that DIF-1 induces phosphorylation of AMPK and Raptor and dephosphorylation of p70S6K in multiple TNBC cell lines. Next, we examined whether AMPK-mediated inhibition of p70S6K leads to the suppression of proliferation and migration/infiltration of TNBC cells. DIF-1 significantly reduced the expression levels of cyclin D1 by suppressing the translation of STAT3 and strongly suppressed the expression levels of Snail, which led to the suppression of growth and motility, respectively. Finally, we investigated whether DIF-1 exerts anticancer effects on TNBC in vivo. Intragastric administration of DIF-1 suppressed tumor growth and spontaneous lung metastasis of 4T1-Luc cells injected into the mammary fat pad of BALB/c mice. DIF-1 is expected to lead to the development of anticancer drugs, including anti-TNBC, by a novel mechanism.
科研通智能强力驱动
Strongly Powered by AbleSci AI